Biotech Values

[DewDiligence]

Clues of omission are pertinent in biotech investing, just as they are in whodunits :- )

I think I can safely say I won't ever be touching IDIX again.

NVS probably wishes it could say the same. All told, from inception, IDIX has turned out to be one of NVS’ worst investments of any kind. I expect NVS to announce a permanent asset-impairment charge on its equity stake when 1Q11 financials are reported in April.